1. Home
  2. BGSF vs IFRX Comparison

BGSF vs IFRX Comparison

Compare BGSF & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BGSF Inc.

BGSF

BGSF Inc.

HOLD

Current Price

$6.00

Market Cap

63.4M

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$0.92

Market Cap

60.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGSF
IFRX
Founded
2007
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.4M
60.6M
IPO Year
2013
2017

Fundamental Metrics

Financial Performance
Metric
BGSF
IFRX
Price
$6.00
$0.92
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$9.00
$8.50
AVG Volume (30 Days)
21.5K
302.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
33.33%
N/A
EPS Growth
67.37
N/A
EPS
N/A
N/A
Revenue
$272,499,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.14
$1,054.36
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.91
$0.71
52 Week High
$8.20
$1.94

Technical Indicators

Market Signals
Indicator
BGSF
IFRX
Relative Strength Index (RSI) 61.90 50.34
Support Level $6.01 $0.73
Resistance Level $6.38 $1.16
Average True Range (ATR) 0.25 0.05
MACD -0.02 0.02
Stochastic Oscillator 59.35 75.05

Price Performance

Historical Comparison
BGSF
IFRX

About BGSF BGSF Inc.

BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: